Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award PDF Print E-mail
Thursday, 17 September 2009 10:52
In a recent Medical News Today article, it was reported that Thomas A. Medsger Jr., M.D.,  Gerald P. Rodnan Professor of Medicine, University of Pittsburgh School of Medicine, received the Scleroderma Foundation's Lifetime Achievement Award in recognition of his service to the Scleroderma community. The award is the foundation's highest honor and is presented to individuals who have devoted a minimum of 20 years of service, either as a volunteer or professional, to the Scleroderma community.

Dr. Medsger has served as chief of the University of Pittsburgh's Division of Rheumatology and Clinical Immunology, and director of the Scleroderma Research Program and UPMC's Scleroderma Clinic. His primary clinical and investigative interest is in Scleroderma and other connective tissue diseases.

In 2001 and 2005, Dr. Medsger was the recipient of the Scleroderma Foundation's Doctor of the Year award. He also has been designated as one of the Best Doctors in America by American Health Magazine for the past two decades and was the recipient of the American College of Rheumatology's Distinguished Rheumatologist Award. Recently, he had the title of "Master" conferred upon him by the American College of Rheumatology - a title awarded to members of high professional competence, ethics and moral standing who have significantly furthered the science of rheumatology.

Dr. Medsger currently serves as the Scleroderma Foundation Western Pennsylvania Chapter's treasurer and interim president. He has written numerous articles for the Foundation's Voice magazine and has published more than 300 journal articles about scleroderma and related diseases.

Read the full article here.
 
More articles :

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» New Study Shows Increased Risk Of Cancer In Scleroderma

patients have a 75% increased risk of cancer compared to the general population, a meta-analysis confirms, leading the authors to recommend screening in these patients.Patients were at particular risk of developing (RR 4.35) and haematological...

» Rare Diseases Day

Febuary 28th, 2010 was Rare Diseases Day, and it was marked with a variety of events and activities all over the world - as well as with plenty of citizen media and online participation. The goal was to raise awareness about so-called. These are...

» Positive Phase II Results for AIMSPRO In Scleroderma Announced

announced yesterday, positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic...

» What Is Vitiligo?

According to the Staff, Vitiligo (vit-ih-LI-go) is a condition in which your skin loses , the pigment that determines the color of your skin, hair and eyes. Vitiligo occurs when the cells that produce melanin die or no longer form melanin, causing...

» What are the Early Symptoms of Scleroderma?

Scleroderma is a term used to describe a group of rare, chronic diseases characterized by unusual tightening and hardening of the connective tissues and skin. There are two major types of : localized, which only affects the skin; and systemic, which...